DeepMed Research

BAYLOR COLLEGE OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1900-10-30

Employees: 10K

Market Cap: -

Website: http://www.bcm.edu

Clinical Trials

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

Phase 1

Completed

Conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma
EBV Positive Plasma Cell Neoplasm
Epstein-Barr Virus-Related Non-Hodgkin Lymphoma

Interventions: Biological: Injection of EBV Specific CTLs

First Posted Date: 2003-04-09

Last Posted Date: 2017-02-15

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 13

Registration Number: NCT00058617

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

Phase 1

Completed

Conditions: Systemic Sclerosis

First Posted Date: 2003-04-09

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 24

Registration Number: NCT00058578

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States

Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)

Phase 1

Completed

Conditions: Epstein-Barr Virus Infections

Interventions: Biological: Intravenous injection of EBV specific CTLS

First Posted Date: 2003-04-09

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 13

Registration Number: NCT00058591

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).

Phase 1

Completed

Conditions: Epstein-Barr Virus Infections
Lymphoproliferative Disorders

Interventions: Biological: Intravenous injection of EBV specific CTLs

First Posted Date: 2003-04-09

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 12

Registration Number: NCT00058604

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

Phase 1

Completed

Conditions: LEUKEMIA

Interventions: Drug: CAMPATH-1H
Drug: Anti-CD45
Drug: Ara-C
Drug: Cyclophosphamide
Drug: Mesna
Radiation: Total Body Irradiation

First Posted Date: 2003-03-28

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 6

Registration Number: NCT00057005

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Phase 1

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: ANTI-CD45
Drug: CAMPATH-1H
Drug: FK506
Drug: Fludarabine
Radiation: Total Body Irradiation
Procedure: Stem cell infusion

First Posted Date: 2003-03-27

Last Posted Date: 2012-06-29

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 24

Registration Number: NCT00056966

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Phase 1

Terminated

Conditions: Inherited Metabolic Storage Diseases

Interventions: Drug: CAMPATH-1H
Drug: Anti-CD45
Drug: FK506
Drug: Fludarabine

First Posted Date: 2003-03-27

Last Posted Date: 2015-09-23

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 2

Registration Number: NCT00056979

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Phase 1

Completed

Conditions: Myelodysplastic Disorders
Leukemia
Multiple Myeloma
Plasma Cell Dyscrasia
Lymphoproliferative Disorders

First Posted Date: 2002-11-01

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 40

Registration Number: NCT00048412

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Phase 1

Terminated

Conditions: Graft Failure

First Posted Date: 2002-11-01

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 40

Registration Number: NCT00048399

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
The Methodist Hospital, Houston, Texas, United States

Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL

Phase 2

Completed

Conditions: Histiocytosis, Langerhans-Cell

First Posted Date: 2002-11-01

Last Posted Date: 2020-01-09

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 20

Registration Number: NCT00048373

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy